Information Provided By: 
Fly News Breaks for January 21, 2020
AMGN
Jan 21, 2020 | 09:26 EDT
As previously reported, Evercore ISI analyst Umer Raffat upgraded Amgen to Outperform from In Line. His EPS view is "well north of consensus" and the Enbrel appeals court hearing is coming up, leading him to evaluate his peak EPS view if he assumes Amgen loses Enbrel. Even in such a theoretical scenario, Raffat sees the company having earnings power of $25 per share in 2025, he tells investors.
News For AMGN From the Last 2 Days
There are no results for your query AMGN
